



MEDI LIFESTYLE LIMITED

(Formerly known as IEV HOLDINGS LIMITED)

(Company Registration Number 201117734D)

(Incorporated in the Republic of Singapore on 26 July 2011)

EXCLUSIVE DISTRIBUTOR AGREEMENTS WITH LANSION BIOTECHNOLOGY CO., LTD

PRESS RELEASE

The Board of Directors (the "**Board**" or "**Directors**") of Medi Lifestyle Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that the Company's indirect wholly owned subsidiaries, HealthPro Marketing Sdn Bhd ("**HPM**") and HealthPro Pharma Pte Ltd ("**HPP**") have signed exclusive distributor agreements (the "**Distributor Agreements**") with Lansion Biotechnology Co.,Ltd ("**Lansion**"), for the Malaysia and Singapore markets respectively, for sales and distribution of its SARS-CoV-2 Neutralizing Antibodies Test Kit (Dry Fluorescence Immunoassay) and its LS-4000 Dry Fluorescence Immunoassay Analyser under the brand name '**LansionBio**'. The agreements are valid for a minimum term of 6 months from the date of product registration in the markets and extendable for an additional 6 months.

Similar to home-based glucose tests, the SARS-CoV-2 Neutralizing Antibodies Test Kit only needs a pin-prick sized blood sample that is swabbed onto a test strip, upon which a lateral flow test will produce a Covid-19 antibody qualitative result within minutes. For a more detailed quantitative analysis, such as the strength of the antibody response, that test strip can be placed in the LS-4000 Dry Fluorescence Immunoassay Analyser. The presence of these neutralizing antibodies is indicative of the immune system's adaptation to Covid-19 infection or vaccination and antibody levels are predictive of the body's immune protection against future symptomatic Covid-19 infection¹.

Lansion Biotechnology Co., Ltd. is a China-based biotechnology company that specializes in research and development for in-vitro diagnostic reagents, devices and test kits. With its international leading technologies, Lansion has achieved certification for ISO13485:2016 Medical Devices - Quality Management Systems, giving confidence to customers that its LansionBio products meet regulatory requirements.

The planned rollout of LansionBio products in Malaysia and Singapore include a product registration process, with the respective health authorities, which is estimated to be completed in the fourth quarter of 2021. Under the Distributor Agreements, HPL and HPP will provide after-sales customer support for LansionBio products in the Malaysia and Singapore markets.

Dato Ken Low, Executive Director & CEO of the Company, commented: "We are delighted to have formalised the business relationship with Lansion Biotechnology Co., Ltd. I look forward to working with Lansion to develop awareness of the capabilities of SARS-CoV-2 Neutralizing Antibodies Test Kit and sales to the medical and clinical centres in Malaysia and Singapore".

¹ [Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection | Nature Medicine;](#)

The Distributor Agreements with Lansion Biotechnology Co., Ltd are not expected to have an impact on the consolidated net tangible assets and earnings per share of the Group for the current financial year ending 31 December 2021.

Save for their shareholdings in the Company, none of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the Distributor Agreements. The Directors are also not aware of any substantial shareholders that have an interest, direct or indirect, in the Distributor Agreements.

Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers.

The Company will make the appropriate announcements as and when there are material developments.

By Order of the Board

Dato' Low Koon Poh
Executive Chairman and Chief Executive Officer
16 August 2021

MEDIA CONTACT

For media queries, please contact;

MEDI LIFESTYLE Limited

Corporate Communications Department

Tel: +65 6299 9881

Jeysie Wong (Mobile +60 13 257 2787, Email: jeysie.wong@medi-lifestyle.com)

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Charmian Lim, at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, telephone: (65) 6232 3210.